Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-1: Nemvaleukin alfa +/- pembrolizumab in advanced solid tumors
NCT02799095Phase 2Completed
- Sponsor
- Mural Oncology
- Start
- Sep 2016
- Primary completion
- Mar 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 7
01
Overview
A Phase 2 trial of nemvaleukin alfa in solid tumor (advanced stage), melanoma, renal cell carcinoma (RCC), sponsored by Mural Oncology. Started Sep 2016; status: completed.
02
Drugs
nemvaleukin alfa
03
Conditions
solid tumor (advanced stage)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02799095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799095.